ClinicalTrials.gg
RecruitingNCT06576583ENCANTOUpdated Mar 24, 2026

Implantation of Engineered Cartilage Grafts for Treatment of Patellofemoral Osteoarthritis Versus Surgical Comparators.

A Phase 2 interventional study of Engineered cartilage graft (N-TEC) and Autologous Matrix Induced Chondrogenesis (AMIC) in Patellofemoral Osteoarthritis, sponsored by University Hospital, Basel, Switzerland. Recruiting at 11 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by University Hospital, Basel, Switzerland · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 131 studies in Osteoarthritis with a site in Germany — 12 open to participants now, 27 under way, 3 of them phase 3. Osteoarthritis · Germany.

Planned enrollment
46th of 98
150 · median 139
Started
2025
with 1 other
Phase 2
19 of 131
2 open now
Primary completion
2029-01
later than 18 of 26 live
Registered
122nd of 131
by date

Among the 131 studies in Osteoarthritis with a site in Germany, this one is the 46th largest by planned enrollment of the 98 interventional ones that give a count, is one of 2 that started in 2025, is one of 19 in phase 2, reaches primary completion later than 18 of the 26 other live ones, and was the 122nd registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

12 of the 131 studies in Osteoarthritis with a site in Germany are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Osteoarthritis with a site in Germany, or all of them as a file.
02

Study summary

ENCANTO is a randomized, controlled, multi-center phase II clinical trial for the treatment of patellofemoral osteoarthritis (PFOA) with an Advanced Therapy Medicinal Product (ATMP), nasal chondrocyte-based tissue engineered cartilage (N-TEC) implantation in comparison with current standard of care depending on the stage of osteoarthritis. The goal of this phase II trial is to evaluate the efficacy of N-TEC treatment in comparison to an active comparator Autologous Matrix Induced Chondrogenesis (AMIC) for early stage PFOA or patellofemoral arthroplasty (PFA) for late stage PFOA.

The N-TEC engineered cartilage graft is obtained by culturing expanded autologous nasal chondrocytes within a collagen type I/III membrane.

Read the detailed description

Knee osteoarthritis (OA) is one of the most common causes for pain and disability with over 260 million people affected worldwide. Recent studies found that knee OA often starts in the patello-femoral compartment of the knee (PFOA) and is diagnosed in \~39% of people with knee pain aged above 30 years. Thus, PFOA and progression to full OA plays a crucial role in the reduction of quality of life of many people and in the raise of healthcare costs.

The goal of this multi-center phase II trial is to (i) evaluate the efficacy of N-TEC treatment in comparison to an active comparator Autologous Matrix Induced Chondrogenesis (AMIC) for early stage PFOA or patellofemoral arthroplasty (PFA) for late stage PFOA based on patient self-assessed questionnaires (Knee Injury and Osteoarthritis Outcome Score, KOOS) and (ii) verify the postulated mode of action, which is expected to be of regenerative nature and will be assessed by evaluation of disease-modification by x- ray and structural regeneration of the osteoarthritic joint destruction by MRI analysis. A total of 150 patients with early stage of PFOA (Iwano grade 1-2; 75 patients) or late stage of PFOA (Iwano grade 3-4; 75 patients) will be enrolled in 11 clinical centers and randomized to either N-TEC implantation or active comparator (AMIC or PFA).

03

Conditions studied

  • Patellofemoral Osteoarthritis

Browse trials for

Keywords

  • Nasal chondrocytes
  • Tissue engineering
  • Knee cartilage
  • Patellofemoral osteoarthritis
  • Autologous Matrix Induced Chondrogenesis (AMIC)
  • Patellofemoral arthroplasty (PFA)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient age is ≥18 and ≤ 70 years at time of screening.
  • Symptomatic PFOA grade 1-4 according to Iwano Classification
  • Chondropathy Grade 3-4 according to ICRS classification of the patella, trochlea femoris or both
  • Baseline score of \<75 on the KOOS-5 subjective knee evaluation.
  • Free range of motion of the affected knee joint or ≤ 5° of extension loss and minimum 125° flexion.
  • Patient is willing and able to give written to participate in the study and to comply with all study requirements, including attending all follow-up visits and assessments and to complete postoperative rehabilitation regimen.
  • Minimum values for women: 120g/l, 150G/l, \<1.3
  • Minimum values for men: Haemoglobin 140g/l, Platelets 150G/l, INR\<1.3
  • Patients have failed to demonstrate adequate response to non-pharmacological interventions (e.g. structured land-based exercise programs) and pharmacological treatment such as topical NSAIDs

Exclusion criteria

Exclusion Criteria:

  • Patient is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol or in a dependency or employment with the sponsor.
  • Patient is unwilling, unable or lacking the capacity to provide
  • Patient is unable to undergo magnetic resonance imaging (MRI)
  • Prior surgical treatment of the target knee within 12 months (Note: prior diagnostic arthroscopy with debridement and lavage are acceptable within 12 months).
  • Radiologically apparent degenerative joint disease of the tibiofemoral joint as determined by X-ray (Kellgren and Lawrence grade > 2) or MRI or pain in the tibiofemoral joint as assessed by clinical examination
  • Patient has excessive varus or valgus deformity (>5°), unless corrected during implantation
  • Patient has a symptomatic meniscus lesion (or removal exceeding ½), as indicated by clinical examination (joint line tenderness and McMurray test positive) and MRI.
  • Patient has a (BMI) >35 kg/m2.
  • Patient has chronic rheumatoid arthritis, and/or infectious arthritis
  • Any concomitant painful or disabling disease of the spine, hips, or lower limbs that would interfere with evaluation of the afflicted knee.
  • Patient has a known immunological suppressive disorder or is taking systemic immunosuppressives.
  • Patient had any intra-articular injections into the affected knee within the last 3 months before baseline visit
  • Instability of anterior, posterior and/or collateral ligaments
  • The patient has a /AIDS infection. (regulatory requirement)
  • The patient has an acute Treponema pallidum (syphilis) infection. (regulatory requirement)
  • The patient has an active or C infection with verified antigens. Patients with a cured hepatitis B or C infection and/or verified antibodies are not excluded. (regulatory requirement)
  • Patient is pregnant, breast feeding or anticipates becoming pregnant within 24 months after surgery.
  • Patient is currently participating or has participated in any other clinical study within 3 months prior to the screening visit.
  • Patient has known current or recent history of illicit drug or alcohol abuse or dependence defined as the continued use of alcohol or drugs despite the development of social, legal or health problems.
  • Patient has any other condition, which, in the opinion of the investigator, would make the patient unsuitable for the study.
  • Known allergies for porcine collagen (scaffold), penicillin or streptomycin (manufacturing)
  • Nail-patella syndrome
  • Patients who will likely benefit from conservative therapy, such as physiotherapy, medical training therapy and pain medication
  • Patients with increased anesthesiological and surgical risks (e.g. known or predicted difficult airway, myocardial infarction \<60 days prior to surgery)
  • Patients with increased bleeding risk (e.g. coagulopathies)
  • Patients on anticoagulants whose anticoagulant therapy cannot be interrupted as appropriate to the given agent(s) and underlying condition
  • Patients with any active infections
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Engineered cartilage graft (N-TEC)-Iwano grade 1-2

    N-TEC is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membranes for 2 weeks to allow cells to produce extracellular matrix containing cartilage specific proteins. The IMP is implanted in the knee at the patellofemoral joint.

    Biological: Engineered cartilage graft (N-TEC)

  • Active comparator
    Autologous Matrix Induced Chondrogenesis-Iwano grade 1-2

    AMIC® Chondro-Gide® combines microfracturing (MFx) with the use of Chondro-Gide®, which covers and protects both the super clot resulting from MFx and the repair tissue.

    Procedure: Autologous Matrix Induced Chondrogenesis (AMIC)

  • Experimental
    Engineered cartilage graft (N-TEC)-Iwano grade 3-4

    N-TEC is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membranes for 2 weeks to allow cells to produce extracellular matrix containing cartilage specific proteins. The IMP is implanted in the knee at the patellofemoral joint.

    Biological: Engineered cartilage graft (N-TEC)

  • Active comparator
    Patellofemoral Arthroplasty (PFA)-Iwano grade 3-4

    Patellofemoral Joint Prosthesis

    Procedure: Patellofemoral Arthroplasty (PFA)

Interventions

  • BiologicalEngineered cartilage graft (N-TEC)

    Nasal chondrocytes based tissue engineered cartilage

  • ProcedureAutologous Matrix Induced Chondrogenesis (AMIC)

    Autologous Matrix Induced Chondrogenesis is performed through bone drilling and covering with Chondro-Gide® to attract bone marrow stem cells

  • ProcedurePatellofemoral Arthroplasty (PFA)

    Surgical implantation of a medical device, Zimmer Gender Solutions Patellofemoral Joint Prosthesis.

06

What researchers measure

Primary outcomes

  1. Knee Injury and Osteoarthritis Outcome Score (KOOS)-5

    Difference in 2-year change (baseline to 24 month follow-up) in the KOOS -5 score between patients undergoing N-TEC tissue implantation and patients receiving AMIC or PFA. Minimum score: 0 Maximum score: 100 (higher score means no knee problems)

    Time frame: 24 months

Secondary outcomes

  1. Knee Injury and Osteoarthritis Outcome questionnaire

    patient self reported questionnaire for pain

    Time frame: until 24 months

  2. Knee Injury and Osteoarthritis Outcome questionnaire

    patient self reported questionnaire for symptoms, activity of daily life, sports and quality of life Minimum score: 0 Maximum score: 100 (higher score means no knee problems)

    Time frame: Until 24 months

  3. Kujala questionnaire

    patient self reported questionnaire for Anterior Knee Pain scale. Minimum score: 0 Maximum score: 100 (no knee problems)

    Time frame: Until 24 months

  4. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score

    Self reported questionnaire to evaluate the condition of patients with osteoarthritis of the knee and hip, including pain, stiffness, and physical functioning of the joints. The instrument contains 24 items measuring 3 sub-scales: physical function (17 items), pain (5 items), and stiffness (2 items). Minimum score: 0 (no knee problems) Maximum score: 96 (worst knee problems)

    Time frame: Until 24 months

  5. EQ-5D-5L questionnaire

    Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.

    Time frame: Until 24 months

  6. Global Rating Of Change (GROC) likert scale

    Widely used score to assess whether the patient condition has gotten worse, better, or stayed the same and to quantify the magnitude of that change. Minimum score: -5 ; maximal score: +5.

    Time frame: Until 24 months

  7. Marx Activity Rating Scale (MARS) score

    This activity-related patient-reported outcome measure is widely used to assess the activity of a patient after treatments of the knee. It assesses how often the patient performs activities (running, cutting, deceleration and pivoting) in his healthiest and more active state. Minimum score: 0; maximum score: 16.

    Time frame: Until 24 months

  8. Morphological analysis

    Morphological analysis with assessment of whole cartilage volume (in mm3) by radiological assessment (MRI)

    Time frame: Until 24 months

  9. Collagen network organization

    Collagen network organization with T2 mapping and RADIOMICS GLCM by radiological assessment (MRI)

    Time frame: Until 24 months

  10. Osteoarthritis grading

    Osteoarthritis grade according to Iwano and Kellgren/Lawrence classification by radiological assessment (X-ray)

    Time frame: Until 24 months

  11. Biovigilance

    Number of adverse events, adverse reactions based on severity, expectedness and relationship to treatment.

    Time frame: Until 24 months

07

Study locations

7 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jan 2029, 42 months after the start.

Of 82 phase 2 interventional studies under Osteoarthritis, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 42 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2024
First posted
Aug 28, 2024
StartActual
Jul 15, 2025
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2030
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06576583
Collaborators
Clinical Trial Unit, University Hospital Basel, Switzerland, Wuerzburg University Hospital, Medical University of Vienna, Videoreha, University of Oulu, Theracell Laboratories, Promove-Biotec GmbH, Maastricht University, Foundation National Reumafonds, Angry@Arthritis, University of Miami, Geistlich Pharma AG, European Union
Responsible party
Sponsor
First posted
Aug 28, 2024
Start date
Jul 15, 2025
Primary completion
Jan 2029 (estimated)
Completion
Jan 2030 (estimated)
Last update
Mar 24, 2026

Study contacts

Marcus Mumme, MD
Contact
marcus.mumme@usb.ch
+41 44 387 29 77
Gyözö Lehoczky, MD
Contact
Gyözö.Lehoczky@ukbb.ch
+41 61 704 2615

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion